Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL4059 | 0.89 | — | — | |
| Cytosine SCHEMBL4657334 | 0.89 | DYRK1A (0.44) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL1330400 | 0.89 | — | — | |
| Cytosine SCHEMBL1330710 | 0.89 | — | — | |
| Cytosine SCHEMBL27602400 | 0.89 | DYRK1A (0.34) | DYRK1ATSHR | |
| Cytosine SCHEMBL218676 | 0.88 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL10767383 | 0.88 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL2406920 | 0.87 | — | — | |
| Cytosine SCHEMBL10623341 | 0.87 | — | — | |
| Cytosine SCHEMBL4065266 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20140005147-A1 | DNA POLYMERASE INHIBITORS COMPOSITION AND METHODS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-01-02 | — | — | US | disclosed |
| US-8524690-B2 | DNA polymerase inhibitors composition and methods | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2374890-B1 | Fen-1 endonucleases, mixtures and cleavage methods | THIRD WAVE TECH INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8288093-B2 | Forming a nucleic acid invasive cleavage structure on a target sequence and cleaving the nucleic acid invasive cleavage structure in a site-specific manner; fluorescence in-situ hybridization detection of cytomegalo virus | THIRD WAVE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2058407-B1 | Invasive cleavage of nucleic acids | THIRD WAVE TECH INC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2354252-B1 | Invasive cleavage of nucleic acids | THIRD WAVE TECH INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8182991-B1 | FEN-1 endonucleases, mixtures and cleavage methods | THIRD WAVE TECHNOLOGIES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-6090543-A | DETECTING THE PRESENCE OF A TARGET NUCLEIC ACID MOLECULE BY MIXING TOGETHER CLEAVAGE MEANS, TARGET NUCLEIC ACID, AND COMPLEMENTARY OLIGONUCLEOTIDES; THEN DETECTING NON-TARGET CLEAVAGE PRODUCTS | THIRD WAVE TECHNOLOGIES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0994964-A1 | DETECTION OF NUCEIC ACIDS BY MULTIPLE SEQUENTIAL INVASIVE CLEAVAGES | THIRD WAVE TECHNOLOGIES, INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0966542-A1 | FEN-1 ENDONUCLEASES, MIXTURES AND CLEAVAGE METHODS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| US-6001567-A | SCREENING FOR TARGET RNA MOLECULE; PROVIDING NUCLEASE, TARGET RNA, AND OLIGONUCLEOTIDES, MIXING, ALLOW ANNEALING, SCREEN FOR NON-TARGET CLEAVAGE PRODUCTS, ELECTROPHORETIC SEPARATION AND VISUALIZATION OF PRODUCTS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5994069-A | FORMING NUCLEIC ACID CLEAVAGE STRUCTURE ON TARGET SEQUENCE AND CLEAVING THE NUCLEIC ACID IN A SITE SPECIFIC MANNER USING STRUCTURE SPECIFIC 5'NUCLEASES THEN ANNEALING COMPLEMENTARY OLIGONUCLEOTIDES TO DETECT TARGET NUCLEIC ACID | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5985557-A | TARGET NUCLEIC ACID AND OLIGONUCLEOTIDE MIXTURE | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0904286-A1 | INVASIVE CLEAVAGE OF NUCLEIC ACIDS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1998042873-A1 | DETECTION OF NUCEIC ACIDS BY MULTIPLE SEQUENTIAL INVASIVE CLEAVAGES | THIRD WAVE TECHNOLOGIES, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998023774-A1 | FEN-1 ENDONUCLEASES, MIXTURES AND CLEAVAGE METHODS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| WO-1997027214-A1 | INVASIVE CLEAVAGE OF NUCLEIC ACIDS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | DYRK1A 906/4885TSHR 4793/4885ADORA2A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.